TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female infants aged from 49 days to 84 days at the time of enrollment.~* The gestation period was 37 weeks or longer, and birth weight was 2.5 kg or more.~* The infants and their parents/legally acceptable representative could comply with all of the scheduled visits in the study and the study requirements related to protocol compliance.~* The parents/legally acceptable representative (LAR) signed the written consent form.~Exclusion Criteria:~* Had previously received Haemophilus influenzae type b vaccine prior to this clinical study.~* Had a plan for vaccination with the vaccine other than those permitted in the protocol based on the standard vaccination schedule.~* Had been contacted with a patient with confirmed Hib infection within 30 days before the study start.~* Had had fever of ≥ 37.5°C within the last 3 days (If measured by tympanic thermometer, fever of 38°C or higher)~* Had or were suspected for immune function disorders; had previously received or were suspected to receive the immunosuppressive therapy; or had received the immunosuppressive therapy within 30 days prior to participating in the study (including systemic corticosteroids or inhalation corticosteroids) (However, it was not the exclusion criteria to have received corticosteroid therapy (prednisolone equivalent ≤ 0.5 mg/kg/day) not more than for 14 consecutive days at least 30 days before their participation in the study).~* Had received the treatment of parenteral immunoglobulin or blood products after birth.~* Had allergic history to be considered due to any component of the vaccine including excipients or preservatives.~* Three preceding generations in an ancestral line were not of Korean heritage.~* Had or were suspected to have significant disorders of blood, heart, liver, kidney, nervous system, respiratory system, or digestive system, or the investigator decided that the evaluation of study objective might be interrupted.~* Had been treated with other investigational drug by participating in another clinical trial within 30 days prior to this study entry, or were participating in another clinical study at that time.~* Had plans to move away from the area of the study site before completing the study.~* Inappropriate to take part in this clinical study in the principal investigator or sub-investigator's opinion, for the reasons other than above criteria.

- Gender: ALL
- Minimum Age: 49 Days
- Maximum Age: 84 Days
- Healthy Volunteers: t

Study Arms:
- LBVH0101 (Type: EXPERIMENTAL): None
- Hiberix (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute non-neoplastic portal vein thrombosis~* Compensated cirrhosis (Child class A-B)~* The onset of PVT is within 1 week.~Exclusion Criteria:~* Decompensated liver disease~* Bleeding tendency or recent bleeding event as bleeding peptic ulcer or oesophageal varices~* Neoplastic invasion of the portal vein~* Renal impairment with the creatinine clearance ≤ 30 ml/min~* Pregnancy and breastfeeding~* Hypersensitivity to rivaroxaban~* Concomitant treatment with another anticoagulant~* Concomitant use of clopidogrel.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- study group (Type: ACTIVE_COMPARATOR): acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis~- treated with rivaroxaban
- control group (Type: PLACEBO_COMPARATOR): acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Participant is a healthy infant~* Participant has received one dose of monovalent hepatitis B vaccine prior to or at 1 month of age~Exclusion Criteria :~* Participant has received more than one dose of monovalent hepatitis B vaccine or hepatitis B based combination vaccine prior to study entry~* Participant has been vaccinated with any acellular pertussis or whole cell pertussis based combination vaccines, haemophilus influenzae type b conjugate, poliovirus, pneumococcal conjugate or pneumococcal polysaccharide, rotavirus, or any combination of the above~* Participant has had a fever ≥38.0°C (≥110.4°F) within 24 hours of study enrollment~* Participant was vaccinated with any non-study vaccine (i.e., inactivated, conjugated, live virus vaccine) within 30 days prior to study enrollment, except for inactivated influenza vaccine which will be permitted 15 days or more prior to enrollment~* Participant has hepatitis B surface antigen (HBsAg) seropositivity (by medical history)~* Participant has a history of haemophilus influenzae type B, hepatitis B, diphtheria, tetanus, pertussis, poliomyelitis, rotavirus, or pneumococcal infection

- Gender: ALL
- Minimum Age: 46 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- V419 (Type: EXPERIMENTAL): V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.
- Control (Type: ACTIVE_COMPARATOR): Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Informed Consent Documents signed prior to screening evaluations~* In good physical and mental health~* Pre-menopausal females 21-34 years of age~* Body mass index (BMI)18-25 kg/m2~* Eligible for intracytoplasmic sperm injection (ICSI)~* Unexplained infertility or partner with mild male factor infertility~* Infertility for at least 12 months before randomization~* Regular menstrual cycles of 24-35 days, presumed to be ovulatory~* Hysterosalpingography, hysteroscopy, or transvaginal ultrasound documenting a uterus consistent with expected normal function~* Transvaginal ultrasound documenting expected normal function of the ovaries~* Early follicular phase serum levels of FSH between 1 and 12 IU/L~* Early follicular phase total antral follicle (diameter 2-10 mm) count ≥ 10 for both ovaries combined~* Willing to accept transfer of one blastocyst in the fresh cycle~* Willing to undergo frozen embryo replacement cycles with transfer of one blastocyst per cycle within the first year after randomisation~Exclusion criteria:~* Known polycystic ovarian syndrome or known endometriosis stage I-IV~* Diagnosed as poor responder in a previous controlled ovarian stimulation (COS) cycle~* Severe ovarian hyperstimulation syndrome (OHSS)in a previous COS cycle~* History of recurrent miscarriage~* Current or past (12 months prior to randomization) abuse of alcohol or drugs, and/or current (last month) intake of more than 14 units of alcohol per week~* Current or past smoking habit of more than 10 cigarettes per day~* Hypersensitivity to any active ingredient or excipients in the medicinal products used in the trial~* Hypersensitivity to gonadotrophin-releasing hormone (GnRH) or any other GnRH analogue~* Previous participation in the trial~* Use of any non registered investigational drugs during 3 months before randomization

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 34 Years
- Healthy Volunteers: f

Study Arms:
- Highly Purified Menotrophin (Type: EXPERIMENTAL): None
- Recombinant FSH (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with COPD \[based on ICD-10 code(J43.x-44.x except J430), as the primary or within the fourth secondary diagnosis and initiated LAMA or ICS/LABA more than twice a year from Jan 1, 2005 to Apr 30 2016\].~* Age \>55 years old~Exclusion Criteria:~* Prescription history with any long acting bronchodilator for maintenance therapy (the patient should be inhaler naïve)~* Prescription history with ipratropium bromide~* Prescription history with Leukotriene receptor antagonist(LTRA) or ICS~* Patients with lung cancer, IPF, ILD or lung transplantation at the time of COPD diagnosis

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LAMA (Type: None): Chronic obstructive pulmonary disease (COPD) patients who were prescribed long-acting muscarinic antagonists (LAMA) monotherapy between 01 January 2005 and 30 April 2015.
- ICS/LABA (Type: None): Chronic obstructive pulmonary disease (COPD) patients who were prescribed a fixed-dose combination (FDC) of inhaled corticosteroid (ICS)/long-acting beta agonists (LABA) between 01 January 2005 and 30 April 2015.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject has provided informed consent prior to initiation of any study-specific activities/procedures~2. Completed the 12-week study visit and did not end IP early during the double-blind treatment period of the AMG 334 20120295 (NCT02066415) parent study, and is appropriate for continued treatment.~Exclusion Criteria:~1. Development of any unstable or clinically significant medical condition, laboratory or electrocardiogram (ECG) abnormality following randomization into the parent study, that in the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.~2. Systolic blood pressure (BP) 160 mm Hg and/or diastolic BP 100 mm Hg or greater at screening/Day 1.~3. Subject who used excluded concomitant medications between week 8 and week 12 of the parent study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 66 Years
- Healthy Volunteers: f

Study Arms:
- Erenumab (Type: EXPERIMENTAL): Participants received erenumab 70 mg once a month (QM) or 140 mg QM by subcutaneous injection for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bacterial Decolonization to Prevent Radiation Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* Diagnosis of a solid tumor of the breast or head and neck with plans for fractionated radiation therapy (≥ 15 fractions) with curative intent~Exclusion Criteria:~* Prior RT to the region of interest~* Existing dermatologic condition affecting the treatment area (eg: atopic dermatitis, psoriasis, and non-healing wounds)~* Known allergy to chlorhexidine or mupirocin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): The purpose of this study is to determine whether bacterial decolonization of the nares and skin prior to treatment with radiotherapy (RT) for patients with cancers of the head and neck or breast, can prevent high-grade radiation dermatitis (RD) and improve quality of life. This study is being conducted because prior studies from this research group have found bacterial colonization in the nose prior to initiation of RT to be associated with an increased risk of high-grade RD. Patients in the treatment arm will receive pretreatment with mupirocin ointment to the nares and chlorhexidine wash to the body while patients in the control arm will receive standard of care treatment. Bacterial cultures will be taken from the nares and skin, and participants will also complete a quality of life questionnaire before and after RT.
- Control (Type: NO_INTERVENTION): Patients in the control arm will be treated according to standard of care without any radiation dermatitis prophylaxis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Digoxin Before Second-Trimester Abortion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least 18 years old~* English or Spanish speaking~* be able to give informed consent~* documented fetal cardiac activity.~Exclusion Criteria:~* significant medical illness or cardiovascular disease~* current use of cardiac or antihypertensive medications~* cardiac arrhythmia on preoperative EKG~* multiple gestation~* morbid obesity (BMI greater than 40)~* known digoxin allergy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- intra-fetal injection (Type: ACTIVE_COMPARATOR): Subjects will receive an intra-fetal digoxin injection one day prior to their second-trimester surgical abortion
- intra-amniotic injection (Type: ACTIVE_COMPARATOR): Subjects will receive an intra-amniotic digoxin injection one day prior to their second-trimester surgical abortion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: n-3 Polyunsaturated Fatty Acids in Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-diabetic morbidly obese patients (BMI \> 40 kg/m2) supposed to undergo bariatric surgery~* Age 20-65 yrs~Exclusion Criteria:~* Acute illness within the last two week~* Known diabetes mellitus or current anti-diabetic medication~* Acquired immunodeficiency (HIV infection)~* Hepatitis or other significant liver disease~* Severe or untreated cardiovascular, renal, pulmonary disease~* Untreated or inadequately treated clinically significant thyroid disease~* Anemia~* Active malignant disease~* Inborn or acquired bleeding disorder including warfarin treatment~* Pregnancy or breast feeding~* Drug intolerability that prohibits the use of the study drug

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- n-3 PUFA (Type: EXPERIMENTAL): None
- Control (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Dapagliflozin Taken Twice-daily

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* Diagnosis of T2DM~* Current antihyperglycaemic treatment with metformin immediate release formulation monotherapy \>/= 1500 mg/day at a stable dose for at least 10 weeks prior to enrolment. Other treatment with OADs within the 10 weeks prior to enrolment is not permitted.~* HbA1c ≥ 6.7% and ≤10.5%, based on central laboratory values from Screening Visit, and Enrolment Visit 1.~Exclusion Criteria:~* Diagnosis of Type 1 diabetes mellitus, known diagnosis of Maturity Onset Diabetes of the Young (MODY) or secondary causes of diabetes mellitus~* History of diabetic ketoacidosis~* Symptoms of poorly controlled diabetes including, but not limited to, marked polyuria, polydipsia, and/or greater than 10% weight loss during the 3 months prior to enrolment~* FPG \>270 mg/dL (\>15.0 mmol/L)~* BMI \>45 kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Dapagliflozin 2.5 mg twice-daily plus open-label metformin
- 2 (Type: EXPERIMENTAL): Dapagliflozin 5.0 mg twice-daily plus open-label metformin
- 3 (Type: EXPERIMENTAL): Dapagliflozin 10 mg once-daily plus open-label metformin
- 4 (Type: PLACEBO_COMPARATOR): Placebo plus open-label metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who has been receiving a stable dose and regimen of GLP-1 analogue over 12 weeks before administration of investigational dug~* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug~* Patients with HbA1c of ≥7.0% and \<10.5%~* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug~Exclusion Criteria:~* Patients with type 1 diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (Cushing's syndrome, acromegaly, etc.)~* Patients with severe diabetic complications (proliferative diabetic retinopathy, stage 4 nephropathy, or serious diabetic neuropathy)~* Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria~* Patients with systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg~* Patients with serious renal or hepatic disease~* Patients with eGFR of \<45 mL/min/1.73 m2~* Patients who are the excessive alcohol addicts~* Patients requiring insulin therapy~* Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canagliflozin (TA-7284) ＋GLP-1 analogue (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete